Paul Grootendorst
Biographic Data
| ID | 5411385 |
|---|---|
| NAME | Paul Grootendorst |
| GIVEN NAMES | Paul |
| FAMILY NAME | Grootendorst |
| SIGNATURE | GROOTENDORST P |
| AFFILIATIONS | University of Toronto |
| ORCID | 0000-0003-1978-2834 |
| VERIFIED | Yes |
| TOTAL WORKS | 11 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 11 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 1997 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
The impact of changing the reference countries on the list prices for patented medicines in Canada
BACKGROUND: Canada's Patented Medicine Prices Review Board (PMPRB) uses external and internal reference pricing (IRP) to regulate patented drug list prices. PMPRB has changed external reference countries from 7 to 11 to include countries with prices closer to the OECD median. We examined the impact on the list prices for patented medicines had the amendment been implemented from 2013. METHODS: Using IQVIA MIDAS® quarterly sales data, we selected …
The effect of patented drug price on the share of new medicines across OECD countries
The Government of Canada plans to implement new controls on the prices of patented drugs sold in Canada. The literature indicates that such controls delay drug launches. The Government of Canada, in its cost benefit analysis of the proposed regulatory changes, claims that they do not. To examine this claim, we use recent OECD country level data to estimate regression models of drug launches. These estimates suggest that higher drug list prices in…
The Opportunity Cost of Capital
The opportunity cost of the capital invested in pharmaceutical research and development (R&D) to bring a new drug to market makes up as much as half the total cost. However, the literature on the cost of pharmaceutical R&D is mixed on how, exactly, one should calculate this "hidden" cost. Some authors attempt to adopt models from the field of finance, whereas other prominent authors dismiss this practice as biased, arguing that it artificially in…
Intended and unintended effects of restrictions on the sale of cigarillos to youth
The policy achieved its goal of reducing youth's consumption of cigarillos, but may have an unintended consequence of increasing their use of regular cigars. Policymakers should address the possibility that youth switch to regular cigars in response to restricted access to cigarillos. Possible ways of discouraging this substituting behaviour include extending the ban to cover all flavoured cigars and mandating a minimum pack size for all cigars, …
Equity in dental care among Canadian households
Alleviating the price barrier to care is a fundamental part of improving equity in dental care in Canada. How people have historically spent money on dental care highlights important gaps in Canadian dental care policy
Impact of Antibiotic Administrative Restrictions on Trends in Antibiotic Resistance
National Catastrophic Drug Insurance Revisited
Paul V. Grootendorst, Michael R. Veall, National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?, Canadian Public Policy / Analyse de Politiques, Vol. 31, No. 4 (Dec., 2005), pp. 341-358
Net Health Plan Savings From Reference Pricing for Angiotensin-Converting Enzyme Inhibitors in Elderly British Columbia Residents
BACKGROUND: Reference drug pricing (RP) is a cost-sharing strategy commonly used to control drug expenditures. Under RP, a benefit plan fully reimburses medications that are equally or less expensive than the reference price, and requires patients to pay the extra cost of therapeutically equivalent but higher priced drugs. Critics argued that drug plan savings are offset by administrative costs and increased spending on other health services. OBJ…
Censoring in statistical models of health status
Health Utilities Index Mark 3
BACKGROUND: The Health Utilities Index Mark 3 (HUI3) is a comprehensive, compact health status classification and health state preference system. The HUI3 system has been included in 4 Canadian population health surveys and numerous clinical trials. OBJECTIVES: To evaluate the construct validity of the HUI3 for the measurement of health-related quality of life (HRQL) and attribute-specific morbidity in respondents to the 1990 Ontario Health Surve…
On Becoming 65 in Ontario
Objectives. The authors assess (1) the effects of first-dollar prescription drug insurance coverage provided by the Ontario Drug Benefit plan at age 65 on prescription drug use by seniors, and (2) the differential effects of this coverage on prescription drug use by seniors with varying levels of health status. Methods. The authors modeled self-reported prescription drug use contained in the 1990 Ontario Health Survey as a function of eligibility…
No prominent works on this page.
On Becoming 65 in Ontario
Objectives. The authors assess (1) the effects of first-dollar prescription drug insurance coverage provided by the Ontario Drug Benefit plan at age 65 on prescription drug use by seniors, and (2) the differential effects of this coverage on prescription drug use by seniors with varying levels of health status. Methods. The authors modeled self-reported prescription drug use contained in the 1990 Ontario Health Survey as a function of eligibility…
Censoring in statistical models of health status
Health Utilities Index Mark 3
BACKGROUND: The Health Utilities Index Mark 3 (HUI3) is a comprehensive, compact health status classification and health state preference system. The HUI3 system has been included in 4 Canadian population health surveys and numerous clinical trials. OBJECTIVES: To evaluate the construct validity of the HUI3 for the measurement of health-related quality of life (HRQL) and attribute-specific morbidity in respondents to the 1990 Ontario Health Surve…
Net Health Plan Savings From Reference Pricing for Angiotensin-Converting Enzyme Inhibitors in Elderly British Columbia Residents
BACKGROUND: Reference drug pricing (RP) is a cost-sharing strategy commonly used to control drug expenditures. Under RP, a benefit plan fully reimburses medications that are equally or less expensive than the reference price, and requires patients to pay the extra cost of therapeutically equivalent but higher priced drugs. Critics argued that drug plan savings are offset by administrative costs and increased spending on other health services. OBJ…
National Catastrophic Drug Insurance Revisited
Paul V. Grootendorst, Michael R. Veall, National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?, Canadian Public Policy / Analyse de Politiques, Vol. 31, No. 4 (Dec., 2005), pp. 341-358
Impact of Antibiotic Administrative Restrictions on Trends in Antibiotic Resistance
Equity in dental care among Canadian households
Alleviating the price barrier to care is a fundamental part of improving equity in dental care in Canada. How people have historically spent money on dental care highlights important gaps in Canadian dental care policy
Intended and unintended effects of restrictions on the sale of cigarillos to youth
The policy achieved its goal of reducing youth's consumption of cigarillos, but may have an unintended consequence of increasing their use of regular cigars. Policymakers should address the possibility that youth switch to regular cigars in response to restricted access to cigarillos. Possible ways of discouraging this substituting behaviour include extending the ban to cover all flavoured cigars and mandating a minimum pack size for all cigars, …
The Opportunity Cost of Capital
The opportunity cost of the capital invested in pharmaceutical research and development (R&D) to bring a new drug to market makes up as much as half the total cost. However, the literature on the cost of pharmaceutical R&D is mixed on how, exactly, one should calculate this "hidden" cost. Some authors attempt to adopt models from the field of finance, whereas other prominent authors dismiss this practice as biased, arguing that it artificially in…
The effect of patented drug price on the share of new medicines across OECD countries
The Government of Canada plans to implement new controls on the prices of patented drugs sold in Canada. The literature indicates that such controls delay drug launches. The Government of Canada, in its cost benefit analysis of the proposed regulatory changes, claims that they do not. To examine this claim, we use recent OECD country level data to estimate regression models of drug launches. These estimates suggest that higher drug list prices in…
The impact of changing the reference countries on the list prices for patented medicines in Canada
BACKGROUND: Canada's Patented Medicine Prices Review Board (PMPRB) uses external and internal reference pricing (IRP) to regulate patented drug list prices. PMPRB has changed external reference countries from 7 to 11 to include countries with prices closer to the OECD median. We examined the impact on the list prices for patented medicines had the amendment been implemented from 2013. METHODS: Using IQVIA MIDAS® quarterly sales data, we selected …
Business (8 works) · Medicine (6 works) · Economics (5 works) · Health Systems, Economic Evaluations, Quality of Life (4 works) · Pharmaceutical Economics and Policy (4 works) · Actuarial science (3 works) · Economic growth (3 works) · Environmental health (3 works) · Public economics (3 works) · Biology (2 works)